PMDAapproval72% confidence
[SHINSA]List of Approved Drugs: April 2004 to February 2026
Source: PMDA
Why This Matters
Why this matters: sets a approval precedent in the same sub-indication (ild) as Merck.
Regulatory Analysis
PMDA document relevant to the signal.
Supporting Context
- Therapeutic area
- Cardiology · Hypercholesterolemia
- Sub-indication
- Ild
Related signal: Merck's LIPFENDRA Approved as First Oral PCSK9 Inhibitor for Hypercholesterolemia